Cited by 265Thyroid Cancer Diagnosis and TreatmentTGF-β signaling in diseasesThyroid Disorders and Treatments

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer

Riesco-Eizaguirre, Garcilaso, Rodríguez, Irene, De la Vieja, Antonio, Costamagna, Eugenia, Carrasco, Nancy, Nistal, Manuel, Santisteban, Pilar·2009·Cancer Research

DOI 10.1158/0008-5472.can-09-1248

Open this paper in CoChat — free account

Abstract

The activating mutation BRAFV600E is a frequent genetic event in papillary thyroid carcinomas (PTC) that predicts a poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radioiodide-refractory metastatic disease. The molecular basis of such an aggressive behavior induced by BRAF remains unclear. Here, we show a mechanism through which BRAF induces NIS repression and promotes epithelial to mesenchimal transition and invasion based on the operation of an autocrine transforming growth factor (TGF)β loop. BRAF induces secretion of functional TGFβ and blocking TGFβ/Smad signaling at multiple levels rescues BRAF-induced NIS repression. Although this mechanism is MAP/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK independent, secreted TGFβ cooperates with MEK-ERK signaling in BRAF-induced cell migration, Matrigel invasion, and EMT. Consistent with this process, TGFβ and other key components of TGFβ signaling, such as TβRII and pSmad2, are overexpressed in human PTC, suggesting a widespread activation of this pathway by locally released TGFβ. Moreover, this high TGFβ/Smad activity is associated with PTC invasion, nodal metastasis, and BRAF status. Interestingly, TGFβ is overexpressed in the invasive front, whereas NIS is preferentially expressed in the central regions of the tumors, suggesting that this negative correlation between TGFβ and NIS occurs locally inside the tumor. Our study describes a novel mechanism of NIS repression in thyroid cancer and provides evidence that TGFβ may play a key role in promoting radioiodide resistance and tumor invasion during PTC progression. [Cancer Res 2009;69(21):8317–25]

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-1248

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 retracted

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
Melillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 305
Retracted
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
Melillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22758 · Cited by 298
Retracted
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R. L., Itoh, S., Kawabata, M., Heldin, N., Heldin, C., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,796
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,223
Cloning and characterization of the thyroid iodide transporter
Dai, G., Levy, O., & Carrasco, N. (1996) · Nature · doi:10.1038/379458a0 · Cited by 1,109
Self-citation
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt, J. S., & Herrera, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1503 · Cited by 1,103
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,036

Show all 37 references

Sorted by citations

Items 101–200 of 265

Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake
Liu, Y., Liu, C., Pan, Y., Zhou, J., Ju, H., & Zhang, Y. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01214-y · Cited by 33
Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAFV600E mutant thyroid cancer cells in 2D and 3D culture
Ingeson-Carlsson, C., Martinez‐Monleon, A., & Nilsson, M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.08.003 · Cited by 33
Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29
Identifying thyroid stem/progenitor cells: advances and limitations
Fierabracci, A. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0183 · Cited by 29
FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment
Ugolini, C., Elisei, R., Proietti, A., Pelliccioni, S., Lupi, C., Borrelli, N., Viola, D., Leocata, P., Vitti, P., Miccoli, P., et al. (2013) · Thyroid · doi:10.1089/thy.2012.0589 · Cited by 29
Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
Narayanan, S., & Colevas, A. D. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0404-6 · Cited by 30
Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer
Bakhsh, T., Alhazmi, S., Farsi, A., Yusuf, A., Alharthi, A., Qahl, S. H., Alghamdi, M. A., Alzahrani, F. A., Elgaddar, O., Ibrahim, M. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58536-3 · Cited by 28
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation
Ayroldi, E., Petrillo, M. G., Marchetti, M. C., Cannarile, L., Ronchetti, S., Ricci, E., Cari, L., Avenia, N., Moretti, S., Puxeddu, E., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0346-y · Cited by 27
Normal vs cancer thyroid stem cells: the road to transformation
Zane, M., Scavo, E., Catalano, V., Bonanno, M., Todaro, M., Maria, R. D., & Stassi, G. (2015) · Oncogene · doi:10.1038/onc.2015.138 · Cited by 27
Activated Conventional T-Cells Are Present in Langerhans Cell Histiocytosis Lesions Despite the Presence of Immune Suppressive Cytokines
Quispel, W. T., Stegehuis-Kamp, J. A., Santos, S. J., Egeler, R. M., & van Halteren, A. G. S. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0190 · Cited by 27
Methylation levels of sodium–iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression
Galrão, A. L., Sodré, A. K. M. B., Camargo, R. Y. A., Friguglietti, C. U. M., Kulcsar, M. A. V., de Lima, E. U., Medeiros-Neto, G. A., & Rubio, I. G. S. (2012) · Endocrine · doi:10.1007/s12020-012-9779-8 · Cited by 27
Modulation of Sodium Iodide Symporter in Thyroid Cancer
Lakshmanan, A., Scarberry, D., Shen, D. H.-Y., & Jhiang, S. M. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0203-0 · Cited by 27
Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma
Gao, Y., Qu, N., Zhang, L., Chen, J.-Y., & Ji, Q. (2015) · Tumor Biology · doi:10.1007/s13277-015-4535-3 · Cited by 27
Refractory thyroid carcinoma: which systemic treatment to use?
Faugeras, L., Pirson, A., Donckier, J. E., Michel, L. A., Lemaire, J., Vandervorst, S., & D'Hondt, L. A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017752853 · Cited by 29
Expression of epithelial‐mesenchymal transition regulators TWIST , SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis
Wu, J., Zhang, Y., Cheng, R.-F., Gong, W., Ding, T., Zhai, Q.-L., Wang, Y., Meng, B., & Sun, B. (2018) · Histopathology · doi:10.1111/his.13778 · Cited by 27
The associations between thyroid-related hormones and the risk of thyroid cancer: An overall and dose-response meta-analysis
Wang, Z., Lin, Y., Jiang, Y., Fu, R., Wang, Y., & Zhang, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.992566 · Cited by 26
Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake
Smith, V. E., Franklyn, J. A., & McCabe, C. J. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0064 · Cited by 26
Systemic treatments for radioiodine-refractory thyroid cancers
Chen, P., Yao, Y., Tan, H., & Li, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1346476 · Cited by 30
RETRACTED ARTICLE: LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer
Zhou, H., Sun, Z., Li, S., Wang, X., & Zhou, X. (2017) · Cancer Gene Therapy · doi:10.1038/s41417-017-0003-0 · Cited by 25
Retracted
Thyroid papillary carcinoma with solid sclerosing change in IgG4‐related sclerosing disease
Ito, M., Naruke, Y., Mihara, Y., So, K., Miyashita, T., Origuchi, T., Nakashima, M., & LiVolsi, V. A. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02701.x · Cited by 24
The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines
Lavarone, E., Puppin, C., Passon, N., Filetti, S., Russo, D., & Damante, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.019 · Cited by 24
A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression
D'inzeo, S., Nicolussi, A., Donini, C. F., Zani, M., Mancini, P., Nardi, F., & Coppa, A. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0233 · Cited by 24
Treatment of Aggressive Thyroid Cancer
Huang, J., Harris, E. J., & Lorch, J. H. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.08.004 · Cited by 24
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma
Mitchell, B. C., Dhingra, J. K., & Mahalingam, M. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000113 · Cited by 24
Activated Leukocyte Cell Adhesion Molecule Expression and Shedding in Thyroid Tumors
Miccichè, F., Riva, L. D., Fabbi, M., Pilotti, S., Mondellini, P., Ferrini, S., Canevari, S., Pierotti, M. A., & Bongarzone, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017141 · Cited by 23
Role of reduced expression of SMAD4 in papillary thyroid carcinoma
D'inzeo, S., Nicolussi, A., Ricci, A., Mancini, P., Porcellini, A., Nardi, F., & Coppa, A. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0044 · Cited by 23
GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers
Lee, J., Jeong, S., Lee, C. R., Ku, C. R., Kang, S., Jeong, J. J., Nam, K., Shin, D. Y., Chung, W. Y., Lee, E. J., et al. (2015) · Medicine · doi:10.1097/md.0000000000000998 · Cited by 22
Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter
Read, M. L., Brookes, K., Thornton, C. E. M., Fletcher, A., Nieto, H. R., Alshahrani, M., Khan, R., de Souza, P. B., Zha, L., Webster, J., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.07.016 · Cited by 22
Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma
Musholt, T. J., Schönefeld, S., Schwarz, C. H., Watzka, F., Musholt, P. B., Fottner, C., Weber, M. M., Springer, E., & Schad, A. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0682-6 · Cited by 22
The Usefulness of Preoperative Thyroid‐Stimulating Hormone for Predicting Differentiated Thyroid Microcarcinoma
Shi, R., Liao, T., Qu, N., Liang, F., Chen, J., & Ji, Q. (2015) · Otolaryngology · doi:10.1177/0194599815618388 · Cited by 22
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
Krayem, M., Najem, A., Journé, F., Morandini, R., Salès, F., Awada, A. H., & Ghanem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25879 · Cited by 21
Retracted
Apigenin in Combination with Akt Inhibition Significantly Enhances Thyrotropin-Stimulated Radioiodide Accumulation in Thyroid Cells
Lakshmanan, A., Doseff, A. I., Ringel, M. D., Saji, M., Rousset, B., Zhang, X., & Jhiang, S. M. (2014) · Thyroid · doi:10.1089/thy.2013.0614 · Cited by 20
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation
Anekpuritanang, T., Uataya, M., Claimon, A., Laokulrath, N., Pongsapich, W., & Pithuksurachai, P. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s308910 · Cited by 19
Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?
Brace, M. D., Wang, J., Petten, M., Bullock, M. J., Makki, F. M., Trites, J. R. B., Taylor, S. M., & Hart, R. D. (2014) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-014-0022-x · Cited by 19
Tumor Microenvironment–Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer
Iesato, A., & Nucera, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_14 · Cited by 19
The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
Yang, L., Sun, L., Jiang, Y., Tang, Y., Li, Z., Zhang, H., Bu, H., & Ye, F. (2015) · International Journal of Endocrinology · doi:10.1155/2015/642046 · Cited by 18
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers
Luckett, K. A., Cracchiolo, J. R., Krishnamoorthy, G. P., Leandro-Garcia, L. J., Nagarajah, J., Saqcena, M., Lester, R., Im, S.-Y., Zhao, Z., Lowe, S. W., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0017 · Cited by 18
V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells
Jiménez‐Mora, E., Tamayo, B. G., Gago, S. D., Lasa, M., Baquero, P., & Chiloeches, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116033 · Cited by 19
Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
Tesselaar, M. H., Smit, J. W. A., Nagarajah, J., Netea-Maier, R. T., & Plantinga, T. S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0134 · Cited by 18
Deiodinases in thyroid tumorigenesis
Stefano, M. A. D., Porcelli, T., Schlumberger, M. J., & Salvatore, D. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0015 · Cited by 17
FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway
Ma, S., Wang, Q., Ma, X., Wu, L., Guo, F., Ji, H., Liu, F., Zhao, Y., & Qin, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-3848-6 · Cited by 17
Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer
Saini, S., Maker, A. V., Burman, K. D., & Prabhakar, B. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.003 · Cited by 17
Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway
Jin, J.-Q., Han, J., Ha, J., Baek, H.-S., & Lim, D. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1155 · Cited by 17
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Lang, M., Longerich, T., & Anamaterou, C. (2023) · Thyroid Research · doi:10.1186/s13044-023-00147-7 · Cited by 16
Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance
Gao, H., Bai, P., Xiao, L., Shen, M., Yu, Q., Lei, Y., Huang, W., Lin, X., Zheng, X., Wei, T., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012404 · Cited by 16
Plasma levels of soluble HLA‐G and cytokines in papillary thyroid carcinoma before and after thyroidectomy
Bertol, B. C., de Araújo, J. N. G., Sadissou, I. A., Sonon, P., Dias, F. C., Bortolin, R. H., de Figueiredo-Feitosa, N. L., de Freitas, L. C. C., Tarrapp, S. R. D. M. H., Ramos, C. C. D. O., et al. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13585 · Cited by 16
Effect of BRAF and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer
Mu, Z., Zhang, Y., Sun, D., Lu, T., & Lin, Y.-S. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.005 · Cited by 16
Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation
Stock, A.-M., Hahn, S. A., Troost, G., Niggemann, B., Zänker, K. S., & Entschladen, F. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.022 · Cited by 16
Parameters of dual-energy CT for the differential diagnosis of thyroid nodules and the indirect prediction of lymph node metastasis in thyroid carcinoma: a retrospective diagnostic study
Li, F., Huang, F., Liu, C., Pan, D., Tang, X., Yan, W., Chen, Z., Qin, Y., & Chen, J. (2022) · Gland Surgery · doi:10.21037/gs-22-262 · Cited by 15
Combined “Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma” Harboring IDH1 R132H and BRAF V600E Mutations
Yamada, S., Kipp, B. R., Voss, J. S., Giannini, C., & Raghunathan, A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000515 · Cited by 15
BRAF activates and physically interacts with PAK to regulate cell motility
McCarty, S., Saji, M., Zhang, X., Knippler, C. M., Kirschner, L. S., Fernández, S., & Ringel, M. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0424 · Cited by 15
A review on the mechanism of iodide metabolic dysfunction in differentiated thyroid cancer
Zhao, Y., Zhong, L., & Yi, H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.09.002 · Cited by 15
MKL1 overexpression predicts poor prognosis in patients with papillary thyroid cancer and promotes nodal metastasis
Cheng, X. F., Xu, S., Pan, J., Zheng, J., Wang, X., Yu, H., Bao, J., Xu, Y., Guan, H., & Zhang, L. (2019) · Journal of Cell Science · doi:10.1242/jcs.231399 · Cited by 14
Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells
Liu, Z., Yang, Y. Z., Zhang, Y., Ye, X.-G., Wang, L., & Xu, G. (2013) · Oncology Reports · doi:10.3892/or.2013.2833 · Cited by 14
Effects of BRAFV600E mutation on Na+/I- symporter expression in papillary thyroid carcinoma
Dong, H., Shen, W., Yan, Y., Jilin, Y., & Zhang, L. (2016) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-016-1545-3 · Cited by 14
Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers
Tarabichi, M., Antoniou, A., Pennec, S. L., Gacquer, D., Aubain, N. D. S., Craciun, L., Cielen, T., Laı̈os, I., Larsimont, D., Andry, G., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02279 · Cited by 14
A Critical Balance Between PAX8 and the Hippo Mediator TAZ Determines Sodium/Iodide Symporter Expression and Function
Fernández-Méndez, C., & Santisteban, P. (2021) · Thyroid · doi:10.1089/thy.2021.0191 · Cited by 13
Self-citation
Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway
Lv, X., Lin, Y., Zhu, X. D., & Cai, X. (2023) · Pharmaceutical Biology · doi:10.1080/13880209.2023.2191645 · Cited by 13
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Hanly, E. K., Rajoria, S., Darżynkiewicz, Z., Zhao, H., Suriano, R., Tuli, N. Y., George, A. L., Bednarczyk, R. B., Shin, E. J., Geliebter, J., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-187 · Cited by 13
BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases
Shen, G., Kou, Y., Liu, B., Huang, R., & Kuang, A. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002142 · Cited by 13
Dimerization of the Sodium/Iodide Symporter
Thompson, R. J., Fletcher, A., Brookes, K., Nieto, H. R., Alshahrani, M. M., Mueller, J. W., Fine, N. H. F., Hodson, D. J., Boelaert, K., Read, M. L., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0034 · Cited by 13
Mutual regulation of TGF-β1, TβRII and ErbB receptors expression in human thyroid carcinomas
Mincione, G., Tarantelli, C., Vianale, G., Marcantonio, M. C. D., Cotellese, R., Francomano, F., Nicola, M. D., Costantini, E., Cichella, A., & Muraro, R. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.06.012 · Cited by 13
Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights
Hiromasa, T., Wakabayashi, H., Watanabe, S., Yamase, T., & Kinuya, S. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0319 · Cited by 14
Autocrine TGFβ1 Opposes Exogenous TGFβ1-Induced Cell Migration and Growth Arrest through Sustainment of a Feed-Forward Loop Involving MEK-ERK Signaling
Ungefroren, H., Christl, J., Eiden, C., Wellner, U. F., Lehnert, H., & Marquardt, J.-U. (2021) · Cancers · doi:10.3390/cancers13061357 · Cited by 12
Basolateral Sorting of the Sodium/Iodide Symporter Is Mediated by Adaptor Protein 1 Clathrin Adaptor Complexes
Koumarianou, P., Fernández-Méndez, C., Fajardo-Delgado, D., Mielu, L. M., Santisteban, P., & la Vieja, A. D. (2022) · Thyroid · doi:10.1089/thy.2022.0163 · Cited by 12
Self-citation
The frequency of mutations in advanced thyroid cancer in Japan: a single-center study
Toda, S., Iwasaki, H., Okubo, Y., Hayashi, H., Kadoya, M., Takahashi, H., Yokose, T., Hiroshima, Y., & Masudo, K. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0342 · Cited by 12
A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2
Alsina, J., Alsina, R., & Güleç, S. (2017) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/2017.26.suppl.12 · Cited by 12
MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma
Gierlikowski, W., Broniarek, K., Cheda, Ł., Rogulski, Z., & Kotlarek, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116067 · Cited by 12
Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome
Winer, D. A., Winer, S., ROTSTEIN, L. E., Asa, S. L., & Mete, Ö. (2012) · Endocrine Pathology · doi:10.1007/s12022-012-9219-6 · Cited by 12
Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
Huang, S., Qi, M., Tian, T., Dai, H., Tang, Y., & Huang, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.959089 · Cited by 11
Mechanistic Aspects of Inflammation and Oxidative Stress and Their Association With Thyroid Cancer Risk
Zhang, B., Guo, M., Lü, Y., Zeng, Y., & Jiang, J. (2025) · Cancer Medicine · doi:10.1002/cam4.71030 · Cited by 11
Cooperative effects of SAHA and VPA on NIS gene expression and proliferation of thyroid cancer cells
Puppin, C., Passon, N., Hershman, J. M., Filetti, S., Bulotta, S., Celano, M., Russo, D., & Damante, G. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0063 · Cited by 11
KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer
Lee, J., Seol, M.-Y., Jeong, S., Kwon, H. J., Lee, C. R., Ku, C. R., Kang, S., Jeong, J. J., Shin, D. Y., Nam, K., et al. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0270 · Cited by 11
Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis
Mohamed, S. Y., Ibrahim, T. R., Elbasateeny, S. S., Abdelaziz, L. A., Farouk, S., Yassin, M. A., & Embaby, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-67615-0 · Cited by 11
Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma
Wieczorek-Szukala, K., Kopczynski, J., Kowalska, A., & Lewinski, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092701 · Cited by 11
Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer
Paladino, S., & Melillo, R. M. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx106 · Cited by 11
β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAFV600E-Driven Thyroid Cancer Animal Model
Zou, M., BinEssa, H. A., Al-Malki, Y. H., Al‐Yahya, S., Al-Alwan, M. M., Al‐Jammaz, I., Khabar, K. S. A., Almohanna, F., Assiri, A. M., Meyer, B. F., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0037 · Cited by 10
Whole-Genome Multiparametric Screening to Identify Modulators of Epithelial-to-Mesenchymal Transition
Said, N. A. B. M., Gould, C. M., Lackovic, K., Simpson, K. J., & Williams, E. D. (2014) · Assay and Drug Development Technologies · doi:10.1089/adt.2014.593 · Cited by 10
Physiological and Pathophysiological Roles of Ion Transporter-Mediated Metabolism in the Thyroid Gland and in Thyroid Cancer
Wang, H., Ma, Z., Cheng, X., Tuo, B., Liu, X., & Li, T. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280797 · Cited by 10
APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma
Siraj, S., Masoodi, T., Siraj, A. K., Azam, S., Qadri, Z., Parvathareddy, S. K., Bu, R., Siddiqui, K. S., Al-Sobhi, S. S., Aldawish, M., et al. (2022) · Cancers · doi:10.3390/cancers14061584 · Cited by 10
Update in Thyroidology 2010
Hershman, J. M., Cheng, S.-Y., & Gianoukakis, A. G. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2350 · Cited by 10
Molecular and Genetic Markers of Follicular-Cell Thyroid Cancer: Etiology and Diagnostic and Therapeutic Opportunities
Goyal, N., Setabutr, D., Abdulghani, J., & Goldenberg, D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_14 · Cited by 10
The role of miR-139-5p in radioiodine-resistant thyroid cancer
Pecce, V., Sponziello, M., Verrienti, A., Grani, G., Abballe, L., Bini, S., Annunziata, S., Perotti, G., Salvatori, M., Zagaria, L., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02059-7 · Cited by 9
A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors
Fenniche, S., Oukabli, M., Oubaddou, Y., Chahdi, H., Damiri, A., Ghuzlan, A. A., Laraqui, A., Dakka, N., Bakri, Y., Dupuy, C., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45070367 · Cited by 9
Molecular regulation of thyroid gland function
Eggo, M. C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833c8942 · Cited by 9
Interplay of TGFβ signaling and microRNA in thyroid cell loss of differentiation and cancer progression
Fuziwara, C. S., Saito, K. C., & Kimura, E. T. (2019) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000172 · Cited by 9
Dedifferentiation and Redifferentiation of Follicular-Cell-Derived Thyroid Carcinoma: Mechanisms and Therapeutic Implications
He, Y., Tang, Z.-M., Xu, M., & Huang, T. (2025) · Biomedicines · doi:10.3390/biomedicines13122982 · Cited by 9
A clinically useful and biologically informative genomic classifier for papillary thyroid cancer
Craig, S. J., Stretch, C., Farshidfar, F., Sheka, D., Alabi, N., Siddiqui, A., Kopciuk, K. A., Park, Y. J., Khalil, M., Khan, F., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220617 · Cited by 9
The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma
Lang, B. H. (2011) · Journal of Thyroid Research · doi:10.1155/2012/198313 · Cited by 8
Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells
Hanly, E. K., Tuli, N. Y., Bednarczyk, R. B., Suriano, R., Geliebter, J., Moscatello, A. L., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6779 · Cited by 8
Network analysis reveals essential proteins that regulate sodium-iodide symporter expression in anaplastic thyroid carcinoma
Rakhsh-Khorshid, H., Samimi, H., Torabi, S., Sajjadi‐Jazi, S. M., Samadi, H., Ghafouri, F., Asgari, Y., & Haghpanah, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-78574-x · Cited by 8
Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis
Chai, Y. J., Kim, Y. A., Jee, H., Yi, J. W., Jang, B. G., Lee, K. E., Park, Y. J., & Youn, Y. (2014) · Surgery · doi:10.1016/j.surg.2014.08.050 · Cited by 8
IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans
Li, J., Yu, Y., Yang, Y., Wang, L., Cao, J., Liang, X., Xiao, X.-Y., Tu, Y., & Chen, H. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04072.x · Cited by 8
Targeted Treatment of Differentiated and Medullary Thyroid Cancer
Bales, S. R., & CHOPRA, I. J. (2011) · Journal of Thyroid Research · doi:10.4061/2011/102636 · Cited by 7
Acceleration of BRAFV600E-induced thyroid carcinogenesis by TGFβ signal deficiency in mice
Shimamura, M. I., Kurashige, T., Kuatov, R., Nakashima, M., & Nagayama, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02298-1 · Cited by 7
Oxidative Stress and Thyroid Disorders
Periyasamy, L., Babu, K. N., Krishnamoorthy, S., Behlen, J. C., Muthusami, S., & Stanley, J. A. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_1 · Cited by 7
Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом
Румянцев, П. О., Fomin, D. K., & Румянцева, У. В. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17650/2222-1468-2014-0-3-4-9 · Cited by 7
Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells
Ingeson-Carlsson, C., & Nilsson, M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.006 · Cited by 7
Mutación del gen BRAF V600E en el cáncer papilar de tiroides y su efecto en la terapia con yodo radiactivo ( 131 I) posquirúrgica: ¿deberíamos modificar nuestra estrategia terapéutica?
Ayala, M. D., Rodríguez, A. E., Bilbao‐González, A., Gabiña, P. M., Rodríguez, T. G., de Zarate, E. R. O., Carrillo, M. G., & Barrios, B. (2018) · Cirugía Española · doi:10.1016/j.ciresp.2018.02.018 · Cited by 7
BRAF V600E Mutation in Papillary Thyroid Cancer and Its Effect on Postoperative Radioiodine (131I) Therapy: Should We Modify Our Therapeutic Strategy?
Ayala, M. D., Rodríguez, A. E., González, A. B., Gabiña, P. M., Rodríguez, T. G., de Zarate, E. R. O., Carrillo, M. G., & Barrios, B. (2018) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2018.05.010 · Cited by 7

Authors: Riesco-Eizaguirre, G., Rodríguez, I., De la Vieja, A., Costamagna, E., Carrasco, N., Nistal, M., & Santisteban, P.
Affiliations: 1Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas y Universidad Autónoma de Madrid; 2Servicio de Endocrinología y Nutrición and 3Departamento de Anatomía Patológica, Hospital Universitario La Paz; and 4Área de Biología Celular y Desarrollo, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; and 5Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York
Albert Einstein College of Medicine (US)
ORCID: Carrasco, Nancy
Santisteban, Pilar
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2009-10-28
Volume: 69
Issue: 21
Pages: 8317-8325
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-09-1248
OpenAlex: W2139518879
Cited by: 265
References: 37
Citations by year: 2026: 10 · 2025: 11 · 2024: 7 · 2023: 13 · 2022: 12 · 2021: 22 · 2020: 11 · 2019: 19 · 2018: 18 · 2017: 13 · 2016: 15 · 2015: 24 · 2014: 23 · 2013: 18 · 2012: 14
FWCI: 11.86
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders: Instituto de Salud Carlos III
National Cancer Institute (R01CA098390, CA098390)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords: BRAF V600E mutation, papillary thyroid carcinoma, TGF-beta, sodium iodide symporter, epithelial-mesenchymal transition, tumor invasion, lymph node metastasis, MEK/ERK signaling, Smad2, TGFBR2, cell migration
MeSH terms: Sodium-Iodide Symporters, Adult, Carcinoma, Papillary, Enzyme-Linked Immunosorbent Assay, Female, Fluorescent Antibody Technique, Humans, Immunoenzyme Techniques, Iodides, Luciferases, Male, Mutation, Neoplasm Invasiveness, RNA, Messenger, Thyroid Neoplasms, Tumor Cells, Cultured, Blotting, Western, Down-Regulation, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Receptors, Transforming Growth Factor beta, Autocrine Communication, Reverse Transcriptase Polymerase Chain Reaction, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, Symporters, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Smad2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks